Peters, S; Dziadziuszko, R; Morabito, A; Felip, E; Gadgeel, SM; Cheema, P; Cobo, M; Andric, Z; Barrios, CH; Yamaguchi, M; Dansin, E; Danchaivijitr, P; Johnson, M; Novello, S; Mathisen, MS; Shagan, SM; Schleifman, E; Wang, J; Yan, M; Mocci, S; Voong, D; Fabrizio, DA; Shames, DS; Riehl, T; Gandara, DR; Mok, T – 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
por prodriguez | Ene 1, 2022 | Publicaciones - CIMO-02 | 0 Comentarios